LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced four oral and two poster presentations related to its AUTO1, AUTO2 and AUTO3 programs at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando, FL.
"We are pleased that AUTO1 data will be presented in three oral presentations at ASH. The data form the basis for our decision to move AUTO1 into a pivotal clinical trial in adult ALL, our highest priority program," said Dr. Christian Itin, chairman and chief executive officer of Autolus. "We are also looking forward to presenting data on our other hematological clinical programs at ASH. These presentations will further illustrate the significant progress we have made across our clinical portfolio this year."
The abstracts have been published today and are available on the ASH website at https://www.hematology.org/Annual-Meeting/Abstracts/.
The oral presentation details are as follows:
Title: AUTO1 – A novel fast off CD19CAR delivers durable remissions and prolonged CAR T cell persistence with low CRS or neurotoxicity in adult ALL
Presenter: Dr Claire Roddie
Session Date and Time: Saturday, December 7, 2:45 PM Eastern Time
Title: AUTO1 – Therapy of pediatric B-ALL with a lower affinity CD19 CAR leads to enhanced expansion and prolonged CAR T cell persistence in patients with low bone marrow tumor burden, and is associated with a favorable toxicity profile
Presenter: Dr Sara Ghorashian
Session Date and Time: Saturday, December 7, 2:30 PM Eastern Time
Title: AUTO1 – Clonal dynamics of early responder and long-term persisting CAR-T cells in humans
Presenter: Dr Luca Biasco
Session Date and Time: Saturday, December 7, 8:15 AM Eastern Time
Title: AUTO3 – Ongoing Phase 1/2 ALEXANDER clinical trial in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL)
Presenter: Dr Kirit Ardeshna
Session Date and Time: Saturday, December 7, 3:15 PM Eastern Time
The poster presentation details are as follows:
Title: AUTO2 – Phase 1 First-in-Human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed/refractory Multiple Myeloma (RRMM)
Presenter: Dr Rakesh Popat
Session Date and Time: Sunday, December 8, 6:00 PM – 8:00 PM Eastern Time
Title: AUTO3 – Phase 1/2 AMELIA clinical trial of AUTO3 in patients with relapsed/refractory pediatric acute lymphoblastic leukemia (pALL)
Presenter: Professor Persis Amrolia
Session Date and Time: Sunday, December 8, 6:00 PM – 8:00 PM Eastern Time
About AUTO1
AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in safety - while maintaining similar levels of efficacy - compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, AUTO1 may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the T cells' abilities to engage in serial killing of target cancer cells. In 2018, Autolus signed a license agreement under which Autolus acquired global rights from UCL Business plc (UCLB), the technology-transfer company of UCL, to develop and commercialize AUTO1 for the treatment of B cell malignancies. AUTO1 is currently being evaluated in two Phase 1 studies, one in pediatric ALL and one in adult ALL.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in pediatric ALL in the AMELIA clinical trial and in diffuse large B cell lymphoma in the ALEXANDER clinical trial.
About AUTO2
AUTO2 is the first dual-targeting programmed T cell product candidate binding to two targets on multiple myeloma cells. AUTO2 uses a human ligand, known as APRIL, which binds to two antigens, B cell Maturation Antigen, or BCMA, and the transmembrane activator and CAML interactor, or TACI, both of which are expressed on the surface of multiple myeloma cancer cells. AUTO2 is designed to address a key escape route used by hematological cancers in response to T cell therapies.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus' financial condition and results of operations, as well as statements regarding the anticipated development of Autolus' product candidates, including its intentions regarding the timing for providing further updates on the development of its product candidates, and the sufficiency of its cash resources. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed on November 23, 2018 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
Investor and media contact:
Silvia Taylor
Vice President, Corporate Affairs and Communications
Autolus
+1-240-801-3850
s.taylor@autolus.com
UK:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
